Dabomb Protein Net Assets
Dabomb Protein net assets. Based on the latest financial reports, Dabomb Protein (6578) has net assets worth NT$989.28 Million TWD (≈ $31.17 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.10 Billion ≈ $34.52 Million USD) and total liabilities (NT$106.48 Million ≈ $3.35 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is Dabomb Protein growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$989.28 Million |
| % of Total Assets | 90.28% |
| Annual Growth Rate | 5.26% |
| 5-Year Change | 46.72% |
| 10-Year Change | 59.62% |
| Growth Volatility | 11.14 |
Net Assets of Dabomb Protein (2015–2025)
Net assets of Dabomb Protein from 2015 to 2025. This chart illustrates how Dabomb Protein's net assets have evolved over time, based on quarterly financial data. See Dabomb Protein balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for Dabomb Protein (2015–2025)
The table below shows the annual net assets of Dabomb Protein from 2015 to 2025. For live market cap and overall valuation, see market cap of Dabomb Protein.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$989.28 Million ≈ $31.17 Million |
-9.18% |
| 2024-12-31 | NT$1.09 Billion ≈ $34.32 Million |
+13.70% |
| 2023-12-31 | NT$958.06 Million ≈ $30.18 Million |
+31.75% |
| 2022-12-31 | NT$727.20 Million ≈ $22.91 Million |
+7.85% |
| 2021-12-31 | NT$674.24 Million ≈ $21.24 Million |
-3.75% |
| 2020-12-31 | NT$700.51 Million ≈ $22.07 Million |
+0.30% |
| 2019-12-31 | NT$698.39 Million ≈ $22.00 Million |
-1.71% |
| 2018-12-31 | NT$710.52 Million ≈ $22.39 Million |
+14.09% |
| 2017-12-31 | NT$622.77 Million ≈ $19.62 Million |
+0.48% |
| 2016-12-31 | NT$619.77 Million ≈ $19.53 Million |
+4.58% |
| 2015-12-31 | NT$592.64 Million ≈ $18.67 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Dabomb Protein's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 145.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Dabomb Protein Net Assets Breakdown (December 2025)
Dabomb Protein net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$1.06 Billion | 106.89% |
| Total Equity | NT$989.28 Million | 100.00% |
Dabomb Protein Competitors by Market Cap
The table below lists competitors of Dabomb Protein ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Koan Hao Technology Co Ltd
TWO:8354
|
$39.34 Million |
|
Retail Food Group Ltd
AU:RFG
|
$39.36 Million |
|
KB No.2 Special Purpose Acq
KQ:192250
|
$39.36 Million |
|
Career Point Limited
NSE:CAREERP
|
$39.37 Million |
|
ESTsoft Corp
KQ:047560
|
$39.31 Million |
|
Donaco International Ltd
AU:DNA
|
$39.30 Million |
|
eSang Networks Co.Ltd
KQ:080010
|
$39.29 Million |
|
IG Group Holdings PLC
LSE:IGG
|
$39.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dabomb Protein's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,089,312,000 to 989,276,000, a change of -100,036,000 (-9.2%).
- Net loss of 69,338,000 reduced equity.
- Dividend payments of 12,230,000 reduced retained earnings.
- Other factors decreased equity by 18,468,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-69.34 Million | -7.01% |
| Dividends Paid | NT$12.23 Million | -1.24% |
| Other Changes | NT$-18.47 Million | -1.87% |
| Total Change | NT$- | -9.18% |
Book Value vs Market Value Analysis
This analysis compares Dabomb Protein's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.26x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.72x to 1.26x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$24.26 | NT$17.35 | x |
| 2018-12-31 | NT$24.29 | NT$17.35 | x |
| 2019-12-31 | NT$23.78 | NT$17.35 | x |
| 2020-12-31 | NT$21.12 | NT$17.35 | x |
| 2021-12-31 | NT$20.76 | NT$17.35 | x |
| 2022-12-31 | NT$18.79 | NT$17.35 | x |
| 2023-12-31 | NT$17.91 | NT$17.35 | x |
| 2024-12-31 | NT$16.02 | NT$17.35 | x |
| 2025-12-31 | NT$13.75 | NT$17.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dabomb Protein utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -22.42%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.11x
- Recent ROE (-7.01%) is below the historical average (0.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 10.49% | 7.73% | 1.10x | 1.23x | NT$2.92 Million |
| 2016 | 11.02% | 9.40% | 0.89x | 1.32x | NT$6.33 Million |
| 2017 | 4.50% | 4.98% | 0.66x | 1.37x | NT$-34.25 Million |
| 2018 | 3.54% | 4.04% | 0.74x | 1.18x | NT$-45.91 Million |
| 2019 | 3.03% | 3.28% | 0.70x | 1.32x | NT$-48.65 Million |
| 2020 | 1.03% | 1.19% | 0.57x | 1.51x | NT$-62.86 Million |
| 2021 | -9.26% | -13.27% | 0.35x | 1.98x | NT$-129.87 Million |
| 2022 | -6.14% | -10.30% | 0.34x | 1.76x | NT$-117.38 Million |
| 2023 | -5.95% | -14.83% | 0.27x | 1.46x | NT$-152.83 Million |
| 2024 | 1.07% | 3.44% | 0.26x | 1.21x | NT$-97.29 Million |
| 2025 | -7.01% | -22.42% | 0.28x | 1.11x | NT$-168.27 Million |
Industry Comparison
This section compares Dabomb Protein's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $9,604,804,100
- Average return on equity (ROE) among peers: 5.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dabomb Protein (6578) | NT$989.28 Million | 10.49% | 0.11x | $39.32 Million |
| Wei Chuan Foods Corp (1201) | $7.23 Billion | 3.32% | 1.43x | $216.84 Million |
| Ve Wong Corp (1203) | $7.42 Billion | 5.80% | 0.41x | $332.51 Million |
| Great Wall Enterprise Co Ltd (1210) | $19.25 Billion | 3.07% | 1.08x | $1.34 Billion |
| Charoen Pokphand Enterprise Taiwan Co Ltd (1215) | $3.28 Billion | 8.30% | 0.69x | $961.26 Million |
| Uni-President Enterprises Corp (1216) | $39.49 Billion | 8.57% | 2.51x | $14.52 Billion |
| AGV Products Corp (1217) | $6.12 Billion | 2.17% | 1.00x | $148.16 Million |
| Taisun Enterprise Co Ltd (1218) | $3.51 Billion | 0.00% | 1.48x | $208.38 Million |
| Fwusow Industry Co Ltd (1219) | $4.44 Billion | 13.85% | 0.92x | $118.80 Million |
| Tai Roun Products Co Ltd (1220) | $1.69 Billion | 0.00% | 0.47x | $59.74 Million |
| Formosa Oilseed Processing Co Ltd (1225) | $3.60 Billion | 7.10% | 0.78x | $195.40 Million |
About Dabomb Protein
DaBomb Protein Biotech Corp. manufactures and sells hydrolyzed soy protein in Vietnam, the Philippines, South Korea, Taiwan, and Asia. It offers plant protein, including DaBomb-P (Aqua) and DaBomb-P (Livestock); antibiotics alternatives, such as DBT-100 HT and DBT-100 LS; and pet care products comprising Liqui-TIDE bandages. The company was formerly known as DaBomb Protein Corp. and changed its n… Read more